ARID1A loss—correlated with microsatellite instability and increased mutation burden across cancer types [12]—has shown favorable prognostic impact—is known to be associated with peritumoral lymphoid aggregates/tumor-infiltrating lymphocytes—in esophageal adenocarcinoma, suggesting the impact of neoantigen-induced immunogenicity on survival [13]. The gene discussed is ARID1A; the disease is cancer.